Live event
Detected Nov 17, 04:07 ETNVSRegulation · Approval or legal win
Novartis Cosentyx® becomes first and only FDA-approved anti-IL-17 biologic for people with polymyalgia rheumatica (PMR)
- What similar events did
- Leans downweak71 of 132 similar events trailed the market
- What happened
- +1.28%vs the market · stock +0.44%Went against the lean
The lean describes how earlier events of the same kind moved after ShockSense detected them; it is recorded at detection and never changed. The move runs from the first tradable price after detection to the close that ends the event's window, measured against the market. Methodology
Alerts for the sectors and news types you choose, and a daily digest after the close, on Telegram or email.
Historical market-reaction analytics for research and educational purposes. Not investment advice. All latest events
